<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01825473</url>
  </required_header>
  <id_info>
    <org_study_id>16220</org_study_id>
    <nct_id>NCT01825473</nct_id>
  </id_info>
  <brief_title>Study of Erythromycin in GER-Associated Apnea of the Newborn</brief_title>
  <acronym>SEGAN</acronym>
  <official_title>Study of Erythromycin in GER-Associated Apnea of the Newborn</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the relationship of reflux and apnea and to determine whether the administration
      of erythromycin improves the incidence of GER and GER-associated apnea, bradycardic and/or
      desaturation events in a prospective randomized controlled trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized placebo-controlled trial to determine whether erythromycin, a drug known to
      enhance gut motility, will improve the incidence of GER and GER-associated apnea,
      bradycardiac and/or hypoxic events. The investigators have two aims: 1) to examine the
      relationship between GER and apnea, bradycardia, and/or desaturation (ABD) events by
      simultaneously employing a unique computer algorithm developed at the University of Virginia
      to measure ABD events and an Multi-channel Intra-luminal Impedance (MII) pH monitoring to
      measure GER episodes. 2) In a randomized placebo-controlled trial, the investigators will
      study whether erythromycin decreases GER and GER-associated apnea, bradycardia and/or hypoxia
      in premature infants.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reflux Impedance events (both acidic and non-acidic) as recorded by Multichannel Intraluminal (MII) pH Impedance</measure>
    <time_frame>during day 6 to 7 of study treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ABD events per Physiologic Monitoring Database</measure>
    <time_frame>during the entire 7 days of treatment</time_frame>
    <description>Number of apnea, bradycardia, and/or desaturation events (ABD) per computer algorithm developed at University of Virginia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ABD events recorded by nursing</measure>
    <time_frame>during the entire 7 days of treatment</time_frame>
    <description>Number of apnea, bradycardia, and/or desaturations (ABD) recorded by bedside nurse</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Gastroesophageal Reflux</condition>
  <condition>Apnea</condition>
  <condition>Bradycardia</condition>
  <arm_group>
    <arm_group_label>Erythromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg/kg/day divided every 6 hours oral for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dextrose 5 Water (D5W) equal amount as experimental every 6 hours oral for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythromycin</intervention_name>
    <arm_group_label>Erythromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Multi-channel intra-luminal impedance (MII) pH monitoring</intervention_name>
    <arm_group_label>Erythromycin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sandhill 6.5 French, product# ZINBS45E</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (D5W)</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Infants admitted to neonatal intensive care unit who are &lt;37 weeks at
        birth and &gt;14 days of age, non-intubated, on full feeds for 3 days with one of the
        following:

          -  Any apnea, bradycardia, or desaturation (ABD) event, or

          -  Documented symptoms of reflux

        Exclusion Criteria:

          -  major central nervous system, gastrointestinal, or complex cardiac anomalies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fara Davalian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fara Davalian, MD</last_name>
    <phone>434-924-5428</phone>
    <email>Fara.Davalian@virginia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Virginia Children's Hospital</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fara Davalian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David A Kaufman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2013</study_first_submitted>
  <study_first_submitted_qc>April 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2013</study_first_posted>
  <last_update_submitted>April 2, 2013</last_update_submitted>
  <last_update_submitted_qc>April 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Faranek Davalian, MD</investigator_full_name>
    <investigator_title>Neonatology Fellow</investigator_title>
  </responsible_party>
  <keyword>neonate</keyword>
  <keyword>apnea</keyword>
  <keyword>preterm</keyword>
  <keyword>reflux</keyword>
  <keyword>gastroesophageal reflux</keyword>
  <keyword>impedance</keyword>
  <keyword>erythromycin</keyword>
  <keyword>desaturation</keyword>
  <keyword>bradycardia</keyword>
  <keyword>hypoxia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Bradycardia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythromycin</mesh_term>
    <mesh_term>Erythromycin Estolate</mesh_term>
    <mesh_term>Erythromycin Ethylsuccinate</mesh_term>
    <mesh_term>Erythromycin stearate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

